Allogene Therapeutics (ALLO) to Release Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) is anticipated to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 5:00 PM ET.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.05. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Stock Down 3.2%

Shares of NASDAQ:ALLO opened at $1.22 on Thursday. The company has a market capitalization of $270.69 million, a price-to-earnings ratio of -1.10 and a beta of 0.43. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $3.78. The firm has a 50 day moving average of $1.21 and a 200 day moving average of $1.25.

Analyst Ratings Changes

A number of equities analysts recently commented on ALLO shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Allogene Therapeutics in a research note on Wednesday, October 8th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Wall Street Zen lowered shares of Allogene Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, October 12th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Allogene Therapeutics in a report on Monday, August 4th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $8.44.

Insider Transactions at Allogene Therapeutics

In other news, CFO Geoffrey M. Parker sold 36,744 shares of the business’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $1.26, for a total transaction of $46,297.44. Following the sale, the chief financial officer directly owned 1,276,796 shares of the company’s stock, valued at $1,608,762.96. The trade was a 2.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 13.20% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

Large investors have recently made changes to their positions in the stock. CANADA LIFE ASSURANCE Co grew its holdings in shares of Allogene Therapeutics by 142.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 31,211 shares of the company’s stock valued at $35,000 after buying an additional 18,314 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in shares of Allogene Therapeutics during the second quarter valued at $37,000. AQR Capital Management LLC purchased a new stake in shares of Allogene Therapeutics during the first quarter valued at $85,000. Rhumbline Advisers grew its holdings in shares of Allogene Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock valued at $237,000 after buying an additional 25,628 shares during the last quarter. Finally, Man Group plc grew its holdings in shares of Allogene Therapeutics by 47.6% during the second quarter. Man Group plc now owns 274,684 shares of the company’s stock valued at $310,000 after buying an additional 88,588 shares during the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).